ArticleArteriosclerosis, thrombosis, and vascular biology2013
Peroxisome proliferator-activated receptor γ coactivator-1α is a central negative regulator of vascular senescence.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- AMPK/ SIRT1 signaling pathway activation acts on PGC-1α/ PPARγ to alleviate sepsis-acquired weakness.Cell death discovery · 2026Article
- Regulation of T Cell Senescence in Health and Diseases.Immune network · 2026Review
- Review
- Regulation of osteogenic differentiation in vascular smooth muscle cells under high-glucose condition.Frontiers in endocrinology · 2025Review
- Telomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway.Experimental & molecular medicine · 2024Article
- Renin-angiotensin system inhibitors positively impact on multiple aging regulatory pathways: Could they be used to protect against human aging?Physiological reports · 2024Review
- Cellular Senescence, Mitochondrial Dysfunction, and Their Link to Cardiovascular Disease.Cells · 2024Review
- Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function.BMC pharmacology & toxicology · 2024Article
- Adjusted vascular contractility relies on integrity of progranulin pathway: Insights into mitochondrial function.bioRxiv : the preprint server for biology · 2023Article
- Targeting Vascular Smooth Muscle Cell Senescence: A Novel Strategy for Vascular Diseases.Journal of cardiovascular translational research · 2023Review
- PGC-1α-mediated angiogenesis prevents pulmonary hypertension in mice.JCI insight · 2023Article
- Article
- Pathophysiology of obesity and its associated diseases.Acta pharmaceutica Sinica. B · 2023Review
- Leukocyte telomere length and mitochondrial DNA copy number associate with endothelial function in aging-related cardiovascular disease.Frontiers in cardiovascular medicine · 2023Article
- The evolving view of thermogenic fat and its implications in cancer and metabolic diseases.Signal transduction and targeted therapy · 2022Review
- New insights of epigenetics in vascular and cellular senescence.Journal of translational internal medicine · 2021Review
- Article
- The mechanisms of vascular aging.Aging medicine (Milton (N.S.W)) · 2021Review
- PGC-1α gene transfer restores adhesion and reendothelialization of endothelial progenitor cells from patients with hypertension.Journal of human hypertension · 2021Article
- The Role of Brown Adipose Tissue Dysfunction in the Development of Cardiovascular Disease.Frontiers in endocrinology · 2021Review
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
Abstract
objectiveCellular senescence influences organismal aging and increases predisposition to age-related diseases, in particular cardiovascular disease, a leading cause of death and disability worldwide. Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) is a master regulator of mitochondrial biogenesis and function, oxidative stress, and insulin resistance. Senescence is associated with telomere and mitochondrial dysfunction and oxidative stress, implying a potential causal role of PGC-1α in senescence pathogenesis. APPROACH AND
resultsWe generated a PGC-1α(+/-)/apolipoprotein E(-/-) mouse model and showed that PGC-1α deficiency promotes a vascular senescence phenotype that is associated with increased oxidative stress, mitochondrial abnormalities, and reduced telomerase activity. PGC-1α disruption results in reduced expression of the longevity-related deacetylase sirtuin 1 (SIRT1) and the antioxidant catalase, and increased expression of the senescence marker p53 in aortas. Further, angiotensin II, a major hormonal inducer of vascular senescence, induces prolonged lysine acetylation of PGC-1α and releases the PGC-1α-FoxO1 complex from the SIRT1 promoter, thus reducing SIRT1 expression. The phosphorylation-defective mutant PGC-1α S570A is not acetylated, is constitutively active for forkhead box O1-dependent SIRT1 transcription, and prevents angiotensin II-induced senescence. Acetylation of PGC-1α by angiotensin II interrupts the PGC-1α-forkhead box O1-SIRT1 feed-forward signaling circuit leading to SIRT1 and catalase downregulation and vascular senescence.
conclusionsPGC-1α is a primary negative regulator of vascular senescence. Moreover, the central role of posttranslational modification of PGC-1α in regulating angiotensin II-induced vascular senescence may inform development of novel therapeutic strategies for mitigating age-associated diseases, such as atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.